Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

NCT07704658 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)
Thyroid Cancer
Solid Tumor Malignancies
Advanced Malignancies

Interventions

DRUG: Pralsetinib
DRUG: CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive

Sponsor

Rigel Pharmaceuticals